Results Of A Dutch Cost-Effectiveness Model Of Radium-223 In Comparison To Cabazitaxel, Abiraterone, And Enzalutamide In Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Docetaxel. (Q53810640)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Results Of A Dutch Cost-Effectiveness Model Of Radium-223 In Comparison To Cabazitaxel, Abiraterone, And Enzalutamide In Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Docetaxel. |
scientific article |
Statements
Results Of A Dutch Cost-Effectiveness Model Of Radium-223 In Comparison To Cabazitaxel, Abiraterone, And Enzalutamide In Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Docetaxel. (English)
1 reference
J Gaultney
1 reference
A Baka
1 reference
A Leliveld-Kors
1 reference
W Noordzij
1 reference
D Wyndaele
1 reference
C De Meyer
1 reference
20 October 2015
1 reference
18
1 reference
7
1 reference
A459
1 reference